News

As a phase III trial of DHE gets underway, the director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about its clinical history in the United States.

The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute spoke about the importance of early treatment and identification of the condition.

A real-world study in relapsing MS helped develop a risk score scale to aid in disability progression prediction, and thus, treatment strategies.

The MS expert discussed the field's recent foray into treating progressive forms of the disease and what is in development.

Xenon Pharmaceuticals announced the expansion of its ion channel pipeline as a result of feedback from the FDA.

The director of the Epilepsy Program at the Banner University Medical Center spoke about the needs in patient populations with epilepsy.

The Johns Hopkins Associate Professor discussed the current of state sleep and also dove into the therapeutic landscape of sleep apnea.

While there isn’t one agent Coyle believes is held above the rest, she noted that the oral therapies have become popular due to ease of administration.

Also known as S48168, it was previously granted Orphan Drug designation as well as a Rare Pediatric Disease designation in 2015 for Duchenne Muscular Dystrophy.

The director of the electromyography laboratory and a professor of neurology at Cedars-Sinai discussed the misdiagnosis of the rare condition.

Neurologic complications remain a significant cause of long-term disability. Understanding and recognizing these conditions is crucial in effectively managing HIV.

The dual-therapy regimen will be compared to high-dose tPA monotherapy, the standard of care, in patients with distal blood clots post-stroke.

Previously, in a 5-year phase I-II trial, the rAAV vector serotype rh.10 showed promising safety data.

The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke about the relationship between primary care and specialists.

Berk spoke to the important partnership between primary care and specialists in neurology.

For ischemic stroke with suspected large-vessel occlusion, regional centralization of care is estimated to result in the best outcomes.

The director of the electromyography laboratory and a professor of neurology at Cedars-Sinai spoke about the treatment options for CIDP.

With the pending decision on 2 more CGRP agents, the need for biomarkers to identify responders has never been greater.

Goadsby spoke about differentiating between the foursome of preventive therapies soon to be available to physicians.

The Saunders Family Professor of Neurology and the director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center discussed the need for biomarkers in MS.

Thomas Berk, MD, discussed the current therapeutic landscape of migraine, emphasizing the importance of conversing with each patient to identify an individualized approach.

David Dodick, MD, a neurologist at Mayo Clinic who’s been involved with multiple trials of headache medicines, provided further insight into the medication class.

A meta-analysis revealed a history of stroke increases dementia risk by around 70%, and recent strokes more than doubled the risk.

The neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic touched on the therapy’s performance in a phase II clinical trial.

Despite supportive preclinical data, no evidence showed that dextroamphetamine in combination with physiotherapy leads to improvement in post-stroke recovery.

Jeffrey Allen, MD, spoke about the breakthrough barrier in CIDP and the importance of the guidelines for diagnosis.

The small molecule slowed atrophy by roughly 2.5 mL less brain-tissue loss compared to placebo.

Results provide Class IV evidence that nusinersen is safe and efficient on motor symptoms in patients older than 7 months of age.